You are here: Home » Reuters » News
Business Standard

Novartis goes after Roche asthma medicine Xolair with new drug

Reuters  |  ZURICH 

ZURICH (Reuters) - Novartis said it is pushing ahead with a late-stage study of its experimental drug ligelizumab after announcing the medicine outperformed Roche's Xolair in a Phase II clinical trial against urticaria, also known as hives.The move sets the stage for a new head-to-head battle between the Swiss drug giants. Xolair had 1.74 billion Swiss francs ($1.75 billion) in sales in 2017 and is a pillar of Roche's immunology franchise, but Novartis sees an opportunity and plans two Phase III studies with more than 2,000 patients who suffer from chronic spontaneous urticaria (CSU).($1 = ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Tue, December 04 2018. 12:32 IST